Company
UCB
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
30
18 still marketed
Novel approvals
11
Approvals since 2021
22
Originals and new uses
Phase 3 trials
189
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Zilbrysq new use OrphanOct 15, 2026
- Kygevvi approved NovelBreakthrough therapyPriority reviewOrphanNov 3, 2025
- Bimzelx new use Nov 19, 2024
- Bimzelx new use Oct 11, 2024
- Bimzelx new use Sep 20, 2024
- Bimzelx new use Sep 20, 2024
- Bimzelx new use Sep 20, 2024
- Cimzia new use Sep 13, 2024
- Zilbrysq approved NovelOrphanOct 17, 2023
- Bimzelx approved NovelOct 17, 2023
Drugs in development (5)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- DZPCDP7657, Dapirolizumab pegolPhase 32 trials
UCB · Systemic Lupus Erythematosus
- Staccato alprazolamUCB7538Phase 32 trials
UCB · Stereotypical Prolonged Seizures
- GalvokimigUCB9741Phase 23 trials
UCB · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis
- UCB0022Phase 21 trial
UCB · Parkinson Disease
- UCB1381Phase 21 trial
UCB · Atopic Dermatitis
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPivotal-lookingRecruiting
NCT06617325 · 450 participants (planned) · Start Nov 21, 2024 · Primary completion May 31, 2028
Drug: DZP · For: Systemic Lupus Erythematosus
Sites: Avondale, Arizona; Chandler, Arizona; Gilbert, Arizona · 245 sites in all
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPivotal-lookingRecruiting
NCT05077904 · 350 participants (planned) · Start Dec 7, 2021 · Primary completion Mar 29, 2027
Drug: Staccato alprazolam · For: Stereotypical Prolonged Seizures
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 183 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisPivotal-lookingRecruiting
NCT07219420 · 320 participants (planned) · Start Nov 14, 2025 · Primary completion Dec 27, 2027
Drug: Bimekizumab; Placebo · For: Palmoplantar Pustulosis
Sites: Birmingham, Alabama; Fremont, California; Miami, Florida · 91 sites in all
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisPivotal-lookingRecruiting
NCT07463521 · 120 participants (planned) · Start May 27, 2026 · Primary completion Dec 1, 2028
Drug: Rozanolixizumab; Placebo · For: Ocular Myasthenia Gravis
Sites: Scottsdale, Arizona; O'Fallon, Illinois; Amherst, New York · 36 sites in all
- A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisPivotal-lookingRecruiting
NCT07465289 · 100 participants (planned) · Start Sep 16, 2026 · Primary completion Mar 17, 2031
Drug: Rozanolixizumab · For: Ocular Myasthenia Gravis
Sites: Scottsdale, Arizona; Columbus, Ohio; Beijing, China · 18 sites in all
NCT06668181 · 40 participants (planned) · Start Mar 11, 2025 · Primary completion Apr 12, 2028
Drug: Bimekizumab · For: Enthesitis-related Arthritis; Juvenile Psoriatic Arthritis
Sites: Calgary, Canada; Montreal, Canada; Saskatoon, Canada · 23 sites in all
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisPivotal-lookingRecruiting
NCT06055959 · 8 participants (planned) · Start Oct 16, 2024 · Primary completion May 12, 2027
Drug: Zilucoplan · For: Generalized Myasthenia Gravis
Sites: Chicago, Illinois; Denton, Texas; Milan, Italy · 9 sites in all
Marketed drugs (18)
Newest FDA action first.
- Zilbrysq Zilucoplan Sodium · 2023
- Fintepla Fenfluramine Hydrochloride · 2020
- Rystiggo Rozanolixizumab-Noli · 2023
- Kygevvi Doxecitine, Doxribtimine · 2025
- Cimzia Certolizumab Pegol · 2008
- Briviact Brivaracetam · 2016
- Briviact Brivaracetam · 2016
- Briviact Brivaracetam · 2016
- Bimzelx Bimekizumab-Bkzx · 2023
- Keppra Levetiracetam · 1999
- Keppra Levetiracetam · 2003
- Keppra Xr Levetiracetam · 2008
- Keppra Levetiracetam · 2006
- Vimpat Lacosamide · 2010
- Vimpat Lacosamide · 2008
- Vimpat Lacosamide · 2008
- Nayzilam Midazolam · 2019
- Neupro Rotigotine · 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.